These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35388271)

  • 21. Magnetic core-shell nanoparticles for drug delivery by nebulization.
    Verma NK; Crosbie-Staunton K; Satti A; Gallagher S; Ryan KB; Doody T; McAtamney C; MacLoughlin R; Galvin P; Burke CS; Volkov Y; Gun'ko YK
    J Nanobiotechnology; 2013 Jan; 11():1. PubMed ID: 23343139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis.
    Suana AJ; Tuffin G; Frey BM; Knudsen L; Mühlfeld C; Rödder S; Marti HP
    J Pharmacol Exp Ther; 2011 May; 337(2):411-22. PubMed ID: 21349934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis.
    Guo L; Luo S; Du Z; Zhou M; Li P; Fu Y; Sun X; Huang Y; Zhang Z
    Nat Commun; 2017 Oct; 8(1):878. PubMed ID: 29026082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of surface modification of As
    Song X; You J; Shao H; Yan C
    Colloids Surf B Biointerfaces; 2018 Sep; 169():289-297. PubMed ID: 29793091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
    Song X; Wang J; Xu Y; Shao H; Gu J
    Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
    Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
    J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabrication of TPGS-Stabilized Liposome-PLGA Hybrid Nanoparticle Via a New Modified Nanoprecipitation Approach: In Vitro and In Vivo Evaluation.
    Zhang M; He J; Zhang W; Liu J
    Pharm Res; 2018 Aug; 35(11):199. PubMed ID: 30167890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local drug delivery using poly(lactic-co-glycolic acid) nanoparticles in thermosensitive gels for inner ear disease treatment.
    Kim DH; Nguyen TN; Han YM; Tran P; Rho J; Lee JY; Son HY; Park JS
    Drug Deliv; 2021 Dec; 28(1):2268-2277. PubMed ID: 34668836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma.
    Ma C; Wei T; Hua Y; Wang Z; Zhang L
    Int J Nanomedicine; 2021; 16():4495-4513. PubMed ID: 34239301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
    Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
    Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis.
    Kanemaru M; Asai J; Jo JI; Arita T; Kawai-Ohnishi M; Tsutsumi M; Wada M; Tabata Y; Katoh N
    J Dermatol Sci; 2019 Jan; 93(1):41-49. PubMed ID: 30655107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diclofenac sodium loaded PLGA nanoparticles for inflammatory diseases with high anti-inflammatory properties at low dose: Formulation, characterization and in vivo HET-CAM analysis.
    Öztürk AA; Namlı İ; Güleç K; Kıyan HT
    Microvasc Res; 2020 Jul; 130():103991. PubMed ID: 32105668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and optimization of crocetin loaded PLGA nanoparticles against diabetic nephropathy via suppression of inflammatory biomarkers: a formulation approach to preclinical study.
    Yang X
    Drug Deliv; 2019 Dec; 26(1):849-859. PubMed ID: 31524015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles.
    Lee C; Seo J; Hwang HS; Thao LQ; Lee S; Lee ES; Lee EH; Choi HG; Youn YS
    Biomed Pharmacother; 2016 Mar; 78():226-233. PubMed ID: 26898446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors.
    Bhatnagar P; Kumari M; Pahuja R; Pant AB; Shukla Y; Kumar P; Gupta KC
    Drug Deliv Transl Res; 2018 Jun; 8(3):565-579. PubMed ID: 29441466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy.
    Ren T; Zheng X; Bai R; Yang Y; Jian L
    Int J Pharm; 2021 May; 601():120583. PubMed ID: 33839225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency.
    Yu F; Ao M; Zheng X; Li N; Xia J; Li Y; Li D; Hou Z; Qi Z; Chen XD
    Drug Deliv; 2017 Nov; 24(1):825-833. PubMed ID: 28509588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated CD4+ T cells target mesangial antigens and initiate glomerulonephritis.
    Scindia Y; Nackiewicz D; Dey P; Szymula A; Bajwa A; Rosin DL; Bolton WK; Okusa MD; Deshmukh U; Bagavant H
    Nephron Exp Nephrol; 2012; 121(1-2):e1-9. PubMed ID: 23095207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
    Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
    Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury.
    Yu H; Jin F; Liu D; Shu G; Wang X; Qi J; Sun M; Yang P; Jiang S; Ying X; Du Y
    Theranostics; 2020; 10(5):2342-2357. PubMed ID: 32104507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.